目的:对文献进行总结,总结行行行行内神经鞘瘤(ILS)切除的耳蜗植入术(CI)的疗效及肿瘤的观察。
方法:OVIDMedline,Embase,WebofScience;到2024年的概念。
方法:使用主题词进行了文献综述,MeSH术语,和关键词。摘要和全文由两名独立审稿人审查,并由第三名审稿人裁决。纳入标准包括ILS和CI的研究,并报告了听力学结果。将受试者分为两组,用CI切除ILS和用CI切除原位ILS。包括NF2患者。感兴趣的主要结果是CI听力测量表现水平,CI用户状态和开放式语音达成的次要结果。
结果:共29篇,共93例患者符合纳入标准。切除组有17%的低表演者,44%的中级表演者,和38%的高表现。原地组有40%的低表演者,32%的中级表演者,27%的高表演者。切除组有69名患者,其中97%保持用户状态,92%使用开放式语音识别。观察组24例,87%的用户率和86%的实现开放式语音识别。在原位组中观察到更高的NF2诊断百分比。
结论:关于CI和ILS的文献很少。通过切除肿瘤和原位植入来管理患者。早期数据有限,随着听力结果的改善和这两个人群的高用户比率。
方法:N/A喉镜,2024.
OBJECTIVE: To evaluate the literature and summarize cochlear implantation (CI) outcomes after intralabyrinthine schwannoma (ILS) excision and tumor observation with CI.
METHODS: OVID Medline, Embase, Web of Science; conception to 2024.
METHODS: A literature
review was performed using subject headings, MeSH terms, and keywords. Abstracts and full texts were reviewed by two independent reviewers and adjudicated by a third. Inclusion criteria included studies with ILS and CI with reported audiologic outcomes. Subjects were analyzed into two groups, ILS resection with CI and in situ ILS with CI. Patients with NF2 were included. The main outcome of interest was CI audiometric performance level, with secondary outcomes of CI user status and open-set speech attainment.
RESULTS: There were 29 articles with a total of 93 patients who met inclusion criteria. The resection group had 17% low performers, 44% intermediate performers, and 38% high performers. The in situ group had 40% low performers, 32% intermediate performers, 27% high performers. The resection group had 69 patients with 97% maintaining user status and 92% with open-set speech recognition. The observation group had 24 patients, with 87% user rate and 86% achieving open-set speech recognition. There was a greater percentage of NF2 diagnosis seen in the in situ group.
CONCLUSIONS: There is a paucity of literature on CI and ILS. Patients are managed with both resection of tumor and implantation in situ. Early data are limited, with improvement in hearing outcomes and high user rates in both populations.
METHODS: N/A Laryngoscope, 134:3910-3920, 2024.